靶向治疗联合同步放化疗治疗晚期非小细胞肺癌患者的可行性

目的探讨靶向治疗联合同步放化疗治疗晚期非小细胞肺癌患者的可行性。方法选取我院收治的162例非小细胞肺癌患者作为研究对象,按治疗方式将其分为观察组(靶向治疗+同步放化疗)和对照组(同步放化疗),各81例。比较两组疾病控制情况、肿瘤标记物、KPS评分及生存情况。结果观察组疾病控制率和疾病缓解率均高于对照组(P<0.05)。治疗后,两组CYFRA21-1及CEA水平均下降,KPS评分均升高,且观察组优于对照组(P<0.05)。观察组1年生存率高于对照组(P<0.05)。结论靶向治疗联合同步放化疗能有效提高晚期非小细胞肺癌患者疾病控制率和缓解率,提高生存率。

Feasibility of targeted therapy combined with concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer

Objective To investigate the feasibility of targeted therapy combined with concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.Methods A total of 162 patients with non-small cell lung cancer admitted in our hospital were selected as the study objects and divided into observation group(targeted therapy+concurrent chemoradiotherapy)and control group(concurrent chemoradiotherapy)according to treatment methods,with 81 cases in each group.The disease control,tumor markers,KPS score and survival were compared between the two groups.Results The disease control rate and disease remission rate of the observation group were higher than those of the control group(P<0.05).After treatment,the levels of CYFRA21-1 and CEA of the two groups decreased,KPS scores increased,and those of the observation group were better than the control group(P<0.05).The 1-year survival rate of the observation group was significantly higher than that of the control group(P<0.05).Conclusion Targeted therapy combined with concurrent chemoradiotherapy can effectively improve the disease control rate and remission rate,and prolong the survival rate in patients with advanced non-small cell lung cancer.